Ultimovacs ASA (STU:7UM)
€ 0.697 -0.044 (-5.94%) Market Cap: 25.01 Mil Enterprise Value: 6.02 Mil PE Ratio: 0 PB Ratio: 0.99 GF Score: 30/100

Q1 2020 Ultimovacs ASA Earnings Call Transcript

May 14, 2020 / 07:00AM GMT
Ã;yvind Arnesen
Ultimovacs ASA - CEO

Good morning, and welcome to this first-quarter 2020 presentation from Ultimovacs. We are streaming from an auditorium in the Oslo Cancer Cluster building.

What I can say is that in the first quarter, the main focus of the company have been to start-up the two trials, the INITIUM trial, and the NIPU trial. We will go through the details about those trials later. And everything that we can control in the startup process for those trials has gone according to the plan. But then as you all know, factors have come in that affect us and that we cannot control.

We will, in this presentation, go through the consequences and what we expect from the trials and in which way they will -- the COVID-19 situation, will affect us. We expected and planned for starting up both INITIUM and the NIPU trial at the end of first quarter, and that was delayed primarily because the hospitals decided that they were unable to perform clinical trials in the situation that they were in in the beginning of March.

However, the hospitals have now opened

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot